Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

15794A022102-NCT05677490OpenRandomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal AdenocarcinomaA022102NCT05677490NationalAdultTreatmentIIIOtherNoel, MarcusGeorgetown University Medical Center : Susan Lawrence; Lombardi Comprehensive Cancer Center : Susan Lawrence; Medstar Washington Hospital CenterGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC)17105Susan LawrenceSusan Lawrencesl2328@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>